New Lymphoma Drug on Horizon

Allos Therapeutics reported that patients with a rare but aggressive form of blood cancer responded to treatment with the company's experimental drug pralatrexate for more than nine months. The result signifies that pralatrexate is having a meaningful benefit for patients, Allos said, and supports the company's effort to get the drug approved in the U.S. later this year. ralatrexate, or perhaps, sell the company outright to a larger drug firm.

A phase II study enrolled 115 patients previously treated for peripheral T-cell lymphoma (PTCL), a fast-growing cancer that affects white blood cells known as T-cells. There are no approved drugs to treat the disease. Of the 109 patients available for evaluation in the study, 29 patients, or 27%, responded to treatment with pralatrexate, including 11 patients whose cancer went into complete remission.

Allos plans to submit pralatrexate for approval to the U.S. Food and Drug Administration during the first half of 2009

LymphomaInfo Social